COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors -: Time to look beyond the FEV1

被引：9

作者：

Celli, B ^{[1
]}

机构：

[1] St Elizabeths Med Ctr, Brighton, MA 02135 USA

来源：

CHEST | 2006年 / 129卷 / 01期

关键词：

D O I：

10.1378/chest.129.1.5

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：5 / 6

页数：2

共 9 条

[1]

[Anonymous], 1980, Ann Intern Med, V93, P391

[2] Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper [J].

Celli, BR ;

MacNee, W ;

Agusti, A ;

Anzueto, A ;

Berg, B ;

Buist, AS ;

Calverley, PMA ;

Chavannes, N ;

Dillard, T ;

Fahy, B ;

Fein, A ;

Heffner, J ;

Lareau, S ;

Meek, P ;

Martinez, F ;

McNicholas, W ;

Muris, J ;

Austegard, E ;

Pauwels, R ;

Rennard, S ;

Rossi, A ;

Siafakas, N ;

Tiep, B ;

Vestbo, J ;

Wouters, E ;

ZuWallack, R .

EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (06) :932-946

[3] Cyclic nucleotide phosphodiesterases [J].

Essayan, DM .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 108 (05) :671-680

[4]

FLENLEY DC, 1981, LANCET, V1, P681

[5] The nature of small-airway obstruction in chronic obstructive pulmonary disease [J].

Hogg, JC ;

Chu, F ;

Utokaparch, S ;

Woods, R ;

Elliott, WM ;

Buzatu, L ;

Cherniack, RM ;

Rogers, RM ;

Sciurba, FC ;

Coxson, HO ;

Paré, PD .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (26) :2645-2653

[6] Mortality by cause for eight regions of the world: Global Burden of Disease Study [J].

Murray, CJL ;

Lopez, AD .

LANCET, 1997, 349 (9061) :1269-1276

[7] Roflumilast -: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease:: a randomised controlled trial [J].

Rabe, KF ;

Bateman, ED ;

O'Donnell, D ;

Witte, S ;

Bredenbröker, D ;

Bethke, TD .

LANCET, 2005, 366 (9485) :563-571

[8] Cilomilast for COPD - Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4 [J].

Rennard, SI ;

Schachter, N ;

Rickard, K ;

Amit, O .

CHEST, 2006, 129 (01) :56-66

[9] Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors [J].

Souness, JE ;

Aldous, D ;

Sargent, C .

IMMUNOPHARMACOLOGY, 2000, 47 (2-3) :127-162

← 1 →